Hemophilia, a rare hematological disease, has been a key focus for Pfizer, and significant progress has been made. A century ago, children with hemophilia, a blood-clotting disorder that causes abnormal bleeding, rarely survived past the age of eight. Today, it is a treatable rare disease, and patients who receive treatment can expect to live relatively normal and active lives. At Pfizer, developing therapies for this disease has been a priority for over 18 years. While there is still no cure, we are moving closer to one with pioneering approaches.